
export const drugData=[
  {
    "cid":"D001",
  "marketInformation": {
    "brandName": "Xalkori",
    "indication": "ALK- or ROS1-positive non‑small cell lung cancer (NSCLC), as well as certain forms of ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors (IMT)",
    "approvedFor": "Pfizer Inc.",
    "approvedCountries": " US,EU.",
    "approvedDate": "2011",
    "genericName": "Generic not available yet",
    "genericApprovedDate": "N/A",
    "potentialGenericAvailability": "Nov, 2029 (based on patent expiration, this can change based on legal challenges and licensing agreements.)",
    "specialStatus": "Orphan Drug Designation available for pediatric ALCL treatment until Jan 14, 2028",
    "patentExclusivityInfo": "",
    "References": ""
  },
  "drugSubstance": {
    "physicalAndChemicalProperties": {
      "chemicalName": "Crizotinib",
      "chemicalStructure": "See media/image1.png",
      "potencyClassification": "",
      "elementalFormula": "C21H22Cl2FN5O",
      "bcsClass": "Class IV (low solubility and low permeability)",
      "molecularWeight": "450.3 g/mol",
      "averageIsotopicMass": "449.11854397 g/mol",
      "structureName": "(R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine",
      "solubility": "Insoluble in water. Solubility decreases as pH increases, dropping from >10 mg/mL at pH 1.6 to <0.1 mg/mL at pH 8.2.",
      "pka": "Has two pKa values: 9.4 (piperidinium cation) and 5.6 (pyridinium cation).",
      "logp": "The partition coefficient (octanol/water) at pH 7.4 is 1.65.",
    "References": ""
    },
    "processDevelopment": {
      "availableDmfVendors": [
        "LGM Pharma",
        "Chongqing Huapont Pharmaceutical",
        "Navinta",
        "Wuxi further pharmaceutical CO"
      ],
      "vendorReference": "http://pharmacompass.com/manufacturers-suppliers-exporters/crizotinib",
      "potencyClassification": "",
      "manufacturingSites": [
        {
          "vendor": "LGM Pharma",
          "location": "USA"
        },
        {
          "vendor": "Chongqing Huapont Pharmaceutical",
          "location": "China"
        },
        {
          "vendor": "Navinta",
          "location": "USA"
        }
      ],
      "manufacturingRoute": "See Appendix 1",
      "polymorphStudies": "Only one crystalline form has been found, thermodynamically stable form A",
      "regulatoryStartingMaterials": "",
      "rsmAndIntermediateSpecifications": "",
      "drugSubstanceSpecifications": "Appendix 2: DS Specification",
      "forcedDegradationStudies": "Stress studies were performed at high temperatures, and no significant degradation was observed after 14 days stored at 100°C. Minor degradation was observed when crizotinib was exposed to strongly acidic, strongly basic, intense light and oxidative conditions.",
      "impurityQualification": "",
      "genotoxicImpuritiesAssessment": "",
      "nitrosaminesAssessment": "",
      "fateOfImpurities": "",
      "cppsAndCqaStudies": "",
      "otherInformation": "",
    "References": ""
    },
    "analyticalDevelopment": {
      "rsmMethods": "",
      "ipcTestMethods": "",
      "finalApiMethods": "",
      "residualSolventRiskAssessment": "",
      "rsmSynthesis": "",
      "stabilityOfDrugSubstance": "",
      "drugSubstanceSites": "Manufacturing, Analytical Testing and Release are performed at: Pfizer Ireland Pharmaceuticals Little Island County Cork Ireland",
      "dsImpurities": "",
      "dsImpurityMethods": "",
    "References": ""
    }
  },
  "drugProduct": {
    "information": {
      "dosageForms": "Capsules, Oral pellets(encapsulated)",
      "strengths": [
        {
          "strength": "200 mg",
          "description": "hard gelatin capsule, size 1, white opaque body and pink opaque cap, with 'Pfizer' on the cap and 'CRZ 200' on the body.",
          "type": "capsule"
        },
        {
          "strength": "250 mg",
          "description": "hard gelatin capsule, size 0, pink opaque cap and body, with 'Pfizer' on the cap and 'CRZ 250' on the body.",
          "type": "capsule"
        },
        {
          "strength": "20 mg",
          "description": "Oral Pellets: hard gelatin capsule, size 4, white opaque body and light blue opaque cap, printed with black ink 'Pfizer' on the cap and 'CRZ 20' on the body.",
          "type": "oral_pellets"
        },
        {
          "strength": "50 mg",
          "description": "Oral Pellets: hard gelatin capsule, size 3, light gray opaque body and gray opaque cap, printed with black ink 'Pfizer' on the cap and 'CRZ 50' on the body.",
          "type": "oral_pellets"
        },
        {
          "strength": "150 mg",
          "description": "Oral Pellets: hard gelatin capsule, size 0, light blue opaque body and cap, printed with black ink 'Pfizer' on the cap and 'CRZ 150' on the body.",
          "type": "oral_pellets"
        }
      ],
      "targetPopulation": "Adults",
      "maximumDailyDose": "1000 mg, 2*250 mg capsules taken twice daily",
      "storageAndShippingConditions": "USP CRT",
      "developmentProgramDesignation": "Xalkori (crizotinib) received multiple developmental program designations from the FDA for different indications, including Breakthrough Therapy, Orphan Drug, Fast Track, Priority Review, and Accelerated Approval. Appendix 3",
      "dpFormulation": "",
      "unmetClinicalNeed": "",
      "manufacturingProcess": "",
      "excipientsgGrade": "",
      "impurities": "",
      "specification": "",
      "testMethods": "",
      "residualSolventsRiskAssessment": "",
      "nitrosamineRiskAssessment": "",
      "stabilityStudies": "",
      "dissolutionStudies": "",
      "baBeStudies": "",
      "foodStudyReports": "",
      "currentLabel": "",
      "dpEmbossingDebossingInfo": "",
      "currentExpirationDating": {
        "oralPellets": "24 months from the date of manufacture",
        "capsules": "15 months from the date of manufacture when first approved by the FDA in 2011. The specific expiration for a particular bottle can be found printed on the outer package."
      },
      "foodInteractions": [
        "Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum levels of crizotinib.",
        "Take with or without food. High-fat food decreases drug absorption, but not to a clinically significant extent."
      ],
      "drugDrugInteractions": [
        "Avoid St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of crizotinib."
      ],
      "packagingAndStorageConditions": {
        "200mg": {
          "description": "Hard gelatin capsule with pink opaque cap and white opaque body, printed with black ink 'Pfizer' on the cap, 'CRZ 200' on the body",
          "packaging": "Bottles of 60 capsules: NDC 0069-8141-20",
          "type": "capsules",
          "storageTemperature": "Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."
        },
        "250mg": {
          "description": "Hard gelatin capsule with pink opaque cap and body, printed with black ink 'Pfizer' on the cap, 'CRZ 250' on the body",
          "packaging": "Bottles of 60 capsules: NDC 0069-8140-20",
          "type": "capsules",
          "storageTemperature": "Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."
        },
        "20mg": {
          "description": "Hard gelatin capsule, size 4, light blue opaque cap and white opaque body, printed with black ink 'Pfizer' on the cap, 'CRZ 20' on the body",
          "packaging": "Bottles of 60 capsules: NDC 0069-0251-60",
          "type": "oral_pellets",
          "storageTemperature": "Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."
        },
        "50mg": {
          "description": "Hard gelatin capsule, size 3, gray opaque cap and light gray opaque body, printed with black ink 'Pfizer' on the cap, 'CRZ 50' on the body",
          "packaging": "Bottles of 60 capsules: NDC 0069-0507-60",
          "type": "oral_pellets",
          "storageTemperature": "Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."
        },
        "150mg": {
          "description": "Hard gelatin capsule, size 0, light blue opaque cap and body, printed with black ink 'Pfizer' on the cap, 'CRZ 150' on the body",
          "packaging": "Bottles of 60 capsules: NDC 0069-1500-60",
          "type": "oral_pellets",
          "storageTemperature": "Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."
        },
        
      },
      "labeling": "Appendix 4: Labeling Information",
      "developmentProgramDesignationDetails": "Appendix 5: Development program designation",
    "References": ""
    }
  },

  "appendices": {
    "appendix1":{
      
      "name": "API Synthetic Route",
      "reference": "https://pubs.acs.org/doi/10.1021/acs.oprd.0c00302",
      "description": "Crizotinib API is manufactured through a stepwise synthetic organic chemistry process that constructs the pyrazole and pyridine rings separately, joins them via ether linkage to the dichloro-fluoroaryl group, and resolves the final product to the R-enantiomer. Manufacturing emphasizes chiral control, impurity management, and recrystallization for purity.",
      "modularSynthesis": {
        "overview": "The synthesis is modular, built from heteroaryl intermediates:",
        "steps": [
          {
            "name": "Pyrazole Core Formation",
            "details": [
              "Constructed from hydrazine derivatives + diketone or equivalent starting materials.",
              "Functionalization introduces the piperidin-4-yl substituent."
            ]
          },
          {
            "name": "Pyridine Intermediate",
            "details": [
              "Prepared via nucleophilic substitution and amination chemistry.",
              "Introduces the amine group at the 2-position."
            ]
          },
          {
            "name": "Ether Coupling",
            "details": [
              "Key step: O-alkylation (ether formation) between the pyridine ring and the dichloro-fluorophenyl moiety.",
              "Typically achieved under basic conditions with appropriate leaving groups."
            ]
          },
          {
            "name": "Chiral Resolution / Enantioselective Step",
            "details": [
              "The API used in Xalkori is the R-enantiomer.",
              "Resolution achieved either by:",
              "Chiral chromatography, or",
              "Diastereomeric salt formation and recrystallization, depending on scale."
            ]
          },
          {
            "name": "Final Purification & Salt Form",
            "details": [
              "API is isolated as crizotinib free base (not a salt form).",
              "Purified by recrystallization, meeting ICH impurity thresholds."
            ]
          },
          {
            "name":"Crizotinib (PF-02341066) | Route overview",
            "details": ["3-position ether on pyridine via Mitsunobu from the benzylic alcohol",
          "5-position aryl–aryl bond via Suzuki–Miyaura to install the pyrazol-4-yl-piperidin-4-yl fragment",
          "Nitro → amine reduction on the pyridine core (gives the 2-amine)"],
          }
        ]
      },
      "processDocumentation": "Pfizer's published process-development paper plus process patents that describe scalable conditions.",
      "synthesisSteps": [
        {
          "step": "A",
          "title": "Chiral benzylic alcohol",
          "description": "Prepare (S)-1-(2,6-dichloro-3-fluorophenyl)ethanol (enantiopure). In Pfizer's enabling route the downstream Mitsunobu inverts this center, delivering the (R) configuration in the API.",
          "links": [
            "https://www.researchgate.net/publication/278699491_Fit-for-Purpose_Development_of_the_Enabling_Route_to_Crizotinib_PF-02341066?utm_source=chatgpt.com"
          ]
        },
        {
          "step": "B",
          "title": "Mitsunobu etherification (installs the 3-ethoxy)",
          "description":"substrates: 5-bromo-3-hydroxy-2-nitropyridine + (S)-benzylic alcohol,conditions: Typical conditions (scaleable): PPh₃ / DIAD, toluene, 0--25 °C → then EtOH crystallization to purge TPPO; delivers 5-bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-2-nitropyridine in ~80--90% yield with retained ee after inversion.yield: ~80--90% yield with retained ee after inversion,",
          "links": [
            "https://www.researchgate.net/publication/278699491_Fit-for-Purpose_Development_of_the_Enabling_Route_to_Crizotinib_PF-02341066?utm_source=chatgpt.com",
            "https://pmc.ncbi.nlm.nih.gov/articles/PMC8173612/?utm_source=chatgpt.com",
            "https://pubs.acs.org/doi/10.1021/acsomega.1c01996?utm_source=chatgpt.com",
            "https://patents.google.com/patent/US9604966B2/en?utm_source=chatgpt.com"
          ]
        },
        {
          "step": "C",
          "title": "Chemoselective nitro → amine reduction (builds the 2-amine)",
          "description":"method: Hydrogenation (H₂, sponge-Ni or Raney-Ni, MeOH, ambient--40 °C) converts the nitro to give (R)-5-bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine.,product: (R)-5-bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine (CAS 877399-00-3)",
          "links": [
            "https://www.lookchem.com/casno877399-52-5.html?utm_source=chatgpt.com",
            "https://www.ruifuchemical.com/cas-877399-00-3-product/?utm_source=chatgpt.com"
          ]
        },
        {
          "step": "D",
          "title": "Pyrazolyl-piperidine boron partner",
          "description": "Prepare 1-(1-Boc-4-piperidinyl)-1H-pyrazol-4-yl boronic acid/ester. This is the coupling partner for the 5-bromo pyridinamine.",
          "links": [
            "https://www.ruifuchemical.com/cas-877399-00-3-product/?utm_source=chatgpt.com",
            "https://patents.google.com/patent/US9604966B2/en?utm_source=chatgpt.com"
          ]
        },
        {
          "step": "E",
          "title": "Suzuki--Miyaura at C-5 of pyridine",
          "description":"substrates: (R)-5-bromo pyridin-2-amine (from Step C) + Boc-protected pyrazolyl-piperidinyl boronic acid,conditions: Representative conditions: Pd(PPh₃)₄, Na₂CO₃ (aq), DMF/H₂O, ∼60 °C, giving the Boc-protected crizotinib precursor in high yield, chromatography-free.",
          "links": [
            "https://patents.google.com/patent/US9604966B2/en?utm_source=chatgpt.com",
            "https://commonorganicchemistry.com/Rxn_Pages/Suzuki/Suzuki.htm?utm_source=chatgpt.com"
          ]
        },
        {
          "step": "F",
          "title": "Global deprotection / finish",
          "description":"method: Acidolysis of Boc (e.g., HCl/EtOH or HCl/dioxane) → neutralization/recrystallization to the free base crizotinib.",
          "links": [
            "https://patents.google.com/patent/US9604966B2/en?utm_source=chatgpt.com",
            "https://www.ema.europa.eu/en/documents/assessment-report/xalkori-epar-public-assessment-report_en.pdf?utm_source=chatgpt.com"
          ]
        },{
            "step": "G",
            "title":"Why this is the industrial route",
            "description":"Chiral center control: single inversion at Mitsunobu gives the desired (R) configuration with no racemization; ee is preserved through downstream steps.Robust scale-ups: chromatography-free EtOH crystallizations purge TPPO; sponge-Ni H₂ reduction and Suzuki run cleanly at moderate T.  Proven at >100 kg scale in Pfizer’s process-development report.",
            "links":[
                "https://www.researchgate.net/publication/278699491_Fit-for-Purpose_Development_of_the_Enabling_Route_to_Crizotinib_PF-02341066?utm_source=chatgpt.com",
                "https://pmc.ncbi.nlm.nih.gov/articles/PMC8173612/?utm_source=chatgpt.com",
                "https://pubs.acs.org/doi/10.1021/op200131n?utm_source=chatgpt.com"
            ]
        }
      ],
      
      "currentManufacturers": "Pfizer sites across the globe"
    },
    "appendix2":{      "name": "DS Specification",
      "specifications": {
        "description": "A white pale-yellow powder. Non-hygroscopic",
        "assay": "",
        "relatedSubstances": "",
        "chiral": "",
        "polymorph": "Amorphous form is used",
        "idByHplc": "",
        "idByFtir": "",
        "particleSizeDistribution": "",
        "residueOnIgnition": "",
        "heavyMetals": "",
        "palladium": "Limit set as per EMA/CHMP/SWP/4666/2000 Option 2a"
      }
    },
    "appendix3":{
            "name": "Formulation Composition",
      "note": "All excipients used in the formulation are compendial and conventional for solid oral dosage forms.",
      "inactiveIngredients": [
        { "ingredientName": "SILICON DIOXIDE (UNII: ETJ7Z6XBU4)", "strength": "" },
        { "ingredientName": "MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)", "strength": "" },
        { "ingredientName": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)", "strength": "" },
        { "ingredientName": "MAGNESIUM STEARATE (UNII: 70097M6I30)", "strength": "" },
        { "ingredientName": "GELATIN, UNSPECIFIED (UNII: 2G86QN327L)", "strength": "" },
        { "ingredientName": "TITANIUM DIOXIDE (UNII: 15FIX9V2JP)", "strength": "" },
        { "ingredientName": "FERRIC OXIDE RED (UNII: 1K09F3G675)", "strength": "" },
        { "ingredientName": "SHELLAC (UNII: 46N107B71O)", "strength": "" },
        { "ingredientName": "PROPYLENE GLYCOL (UNII: 6DC9Q167V3)", "strength": "" },
        { "ingredientName": "AMMONIA (UNII: 5138Q19F1X)", "strength": "" },
        { "ingredientName": "POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)", "strength": "" },
        { "ingredientName": "FERROSOFERRIC OXIDE (UNII: XM0M87F357)", "strength": "" },
        { "ingredientName": "SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D)", "strength": "" }
      ]
    },
    "appendix4":{
      
      "name": "Labeling Information",
      "labels": [
        { "label": "250 mg Capsule Bottle", "image": "image2" },
        { "label": "200 mg Capsule Bottle", "image": "image3" },
        { "label": "20 mg Oral Pellets", "image": "image4" },
        { "label": "50 mg Oral Pellets", "image": "image5" },
        { "label": "150 mg Oral Pellets", "image": "image6" }
      ]
    },
    "appendix5":{
            "name": "Development Program Designation",
      "description": "Xalkori (crizotinib) received multiple developmental program designations from the FDA for different indications, including Breakthrough Therapy, Orphan Drug, Fast Track, Priority Review, and Accelerated Approval.",
      "designations": {
        "Breakthrough Therapy": [
          "ROS1-positive non-small cell lung cancer (NSCLC): In April 2015, the FDA granted Breakthrough Therapy status for Xalkori in treating patients with ROS1-positive NSCLC.",
          "MET exon 14 alterations: In May 2018, Xalkori received Breakthrough Therapy designation for treating patients with metastatic NSCLC who have MET exon 14 alterations.",
          "ALK-positive anaplastic large cell lymphoma (ALCL): At the same time in May 2018, it also received this designation for treating relapsed or refractory ALK-positive ALCL."
        ],
        "Orphan Drug": [
          "Anaplastic lymphoma kinase (ALK)-positive NSCLC: This designation was given in September 2010 to encourage the development of the drug for this rare form of lung cancer.",
          "ALK-positive anaplastic large cell lymphoma (ALCL): In September 2012, Xalkori was designated as an Orphan Drug for ALCL.",
          "ALK-positive inflammatory myofibroblastic tumor (IMT): The FDA also granted this designation for treating ALK-positive IMT."
        ],
        "Fast Track": [
          "ALK-positive advanced NSCLC: This designation was given in December 2010 to expedite the review of Xalkori for patients with ALK-positive NSCLC."
        ],
        "Accelerated Approval and Priority Review": [
          "ALK-positive NSCLC: The FDA granted accelerated approval for Xalkori for ALK-positive NSCLC in August 2011, reflecting the drug's potential for a serious condition.",
          "ROS1-positive NSCLC: In March 2016, the FDA approved Xalkori for ROS1-positive NSCLC and granted the application Priority Review status."
        ]
      }
    }
  },


  "references": [
    {
      "title": "Pfizer OPRD process paper (six-step enabling route; Mitsunobu ↔ Suzuki ↔ H₂/Ni): de Koning et al. 2011.",
      "url": "https://pubs.acs.org/doi/10.1021/op200131n"
    },
    {
      "title": "Process patent with explicit conditions (Mitsunobu in THF/toluene; Suzuki in DMF/Na₂CO₃; Boc deprotection HCl/EtOH): US 9,604,966.",
      "url": "https://patents.google.com/patent/US9604966B2/en"
    },
    {
      "title": "J. Med. Chem. chemistry note (Mitsunobu of 5-bromo-3-hydroxy-2-nitropyridine alcoholates to intermediates): design paper.",
      "url": "https://pubs.acs.org/doi/10.1021/jm401805h"
    },
    {
      "title": "Commercial intermediates listing (confirms structures/CAS used on route): Ruifu Chemical.",
      "url": "https://www.ruifuchemical.com/cas-877399-00-3-product/"
    },
    {
      "title": "EMA EPAR (API as free base in product): Xalkori (crizotinib).",
      "url": "https://www.ema.europa.eu/en/documents/assessment-report/xalkori-epar-public-assessment-report_en.pdf"
    }
  ]
},
{
  "cid": "D002",
  "marketInformation": {
    "brandName": "Exblifep (cefepime and enmetazobactam)",
    "indication": "complicated urinary tract infections (cUTI) including pyelonephritis, caused by susceptible strains of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex.",
    "approvedFor": "Allecra Therapeutics",
    "approvedCountries": "United States, European Union, United Kingdom, Switzerland, Norway, Gulf Cooperation Council (GCC) Countries: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, South Africa",
    "approvedDate": "22 Feb 2024",
    "genericName": "Cefepime and enmetazobactam",
    "genericApprovedDate": "N/A",
    "potentialGenericAvailability": "Not available",
    "specialStatus": "Exblifep (cefepime and enmetazobactam) has been granted several special statuses by the U.S. Food and Drug Administration (FDA) to incentivize the development of new anti-infective drugs. These statuses, which were granted to Exblifep's manufacturer, Allecra Therapeutics, include: Qualified Infectious Disease Product (QIDP) status: This designation is given to antibacterial or antifungal drugs that treat serious or life-threatening infections. QIDP is intended to combat the growing threat of antimicrobial resistance. Fast Track designation: This process is designed to expedite the review of drugs that treat serious conditions and fill an unmet medical need. These designations provided Allecra with significant incentives: Priority Review: QIDP status makes the drug eligible for a faster-than-normal review process by the FDA. Market Exclusivity Extension: Under the Generating Antibiotic Incentives Now (GAIN) Act, which created the QIDP designation, Exblifep was awarded an additional five years of market exclusivity.",
    "patentExclusivityInfo": "Exblifep has patent exclusivity information that includes an estimated generic launch date in November 2034, a 5-year market exclusivity extension through the GAIN Act, and several US patents filed in 2024 that have not yet expired. Its patent challenges can begin in 2033.",
    "References": ""
  },
  "drugSubstance": {
    "physicalAndChemicalProperties": {
      "chemicalName": {
        "Cefepime": "1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium, monochloride, monohydrate.",
        "Enmetazobactam": "(2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate."
      },
      "chemicalStructure": {
        "Cefepime": "structure image",
        "Enmetazobactam": "structure image"
      },
      "potencyClassification": "",
      "elementalFormula": {
        "Cefepime": "C19H24N6O5S2",
        "Enmetazobactam": "C11H14N4O5S"
      },
      "bcsClass": {
        "Cefepime": "BCS Class III",
        "Enmetazobactam": "Not available"
      },
      "molecularWeight": {
        "Cefepime": "480.6 g/mol",
        "Enmetazobactam": "314.32 g/mol"
      },
      "averageIsotopicMass": {
        "Cefepime": "480.12496023 Da (monoisotopic mass)",
        "Enmetazobactam": "314.06849073 Da"
      },
      "structureName": "",
      "solubility": {
        "Cefepime": {
          "cefepimeHydrochloride": {
            "description": "The form of cefepime used for injectable medication is a hydrochloride salt, which is formulated for high solubility in water.",
            "water": "It is highly and easily soluble in water. The hydrochloride salt is added to the formulation specifically to enhance its aqueous solubility.",
            "aqueousSolutions": "Cefepime hydrochloride is readily soluble in various aqueous solutions, including IV solutions and phosphate-buffered saline (PBS). A solubility of approximately 10 mg/ml in PBS (pH 7.2) has been reported.",
            "methanol": "Cefepime dihydrochloride hydrate is reported as soluble in methanol.",
            "ethanol": "It is only slightly soluble in ethanol."
          },
          "pureCefepime": {
            "description": "The base compound, which is a zwitterion (containing both positive and negative charges), is less soluble in water than its hydrochloride salt.",
            "water": "Pure cefepime is considered only slightly soluble or sparingly soluble in water. PubChem reports a solubility of 0.0173 mg/ml in water.",
            "dmso": "It is soluble in organic solvents like dimethyl sulfoxide (DMSO). For example, cefepime hydrochloride hydrate has a solubility of about 0.2 mg/ml in DMSO"
          }
        },
        "Enmetazobactam": {
          "dmso": "Enmetazobactam is known to be soluble in DMSO, a common solvent in scientific research.",
          "ethanol": "soluble in Ethanol",
          "water": "It is sparingly soluble in pure water, meaning its solubility is less than 1 mg/mL.",
          "formulationWithSBECD": "Formulations combining enmetazobactam with sulfobutylether-β-cyclodextrin (SBE-β-CD) in saline can achieve higher concentrations, such as ≥ 2.08 mg/mL.",
          "solventCombinations": "When preparing the drug for use in animal studies, protocols combine DMSO stock solution with 20% SBE-β-CD in Saline to create a higher concentration solution.",
          "concentrationAndTemperature": "Solubility can increase with higher concentration or elevated temperatures, as seen with its solubility in water at 40°C compared to 25°C."
        }
      },
      "pka": {
        "Cefepime": {
          "strongestAcidic": "2.82 (predicted) Chemaxon",
          "strongestBasic": "3.62 (predicted)"
        },
        "Enmetazobactam": {
          "strongestAcidic": "2.09 (predicted) (Chemaxon)",
          "strongestBasic": "2.83 (predicted)"
        }
      },
      "logp": {
        "Cefepime": {
          "alogps": "-0.37 (predicted)",
          "chemaxon": "-4.2 (predicted)"
        },
        "Enmetazobactam": {
          "chemaxon": "-4.6 (predicted)"
        }
      },
      "References": ""
    },
    "processDevelopment": {
      "availableDmfVendors": {
        "Cefepime": "https://www.pharmacompass.com/manufacturers-suppliers-exporters/cefepime",
        "Enmetazobactam": "Orchid Pharma is the primary supplier of enmetazobactam API, as it received DCGI approval to manufacture and market the API. It also partners with other companies, such as Cipla, for commercialization and launch. Out-licensing: Orchid Pharma out-licensed the drug to Allecra Therapeutics for global development as combination of cefepime and enmetazobactam (Exblifep) and commercialization, while retaining the Indian market and royalties."
      },
      "vendorReference": "",
      "potencyClassification": {
        "CefepimeHydrochloride": "One material safety data sheet (MSDS) sets a specific OEL for cefepime hydrochloride at 500 g/m3. Other SDS documents note that official agencies like OSHA or ACGIH have not established an OEL for cefepime, so the OEL would be based on the manufacturer's internal guidance.",
        "Enmetazobactam": "No information found"
      },
      "manufacturingSites": {
        "Cefepime": "Orchid pharma, Kopran R.L, Sterile India, Nectar life sciences, Actiza Pharmacutical, SETV Global, NCPC Hebei Huamin pharmaceutical Co, Ltd, Qilu pharmaceutical, Sinoway industrial Co; Ltd, Hangzhou Viwa, Guangzhou Pi&Pi Biotech, Shenzhen SalubrisACS Dobfar, Sandoz, Corden pharma, Berr chem, API Corp, Antibioticos do Brasila",
        "Enmetazobactam": "Orchid Pharma"
      },
      "manufacturingRoute": {
        "route1": {
          "name": "Route using 7-ACA and N-methylpyrrolidine",
          "description": "This pathway involves three main steps, as outlined in a Google Patent filing.",
          "synthesisDetails": "Synthesis details based on patent CN107201391B. A representative synthetic route found in patent literature, which is likely similar to an industrial process like Orchid's, is as follows:",
          "steps": [
            {
              "step": "Step 1",
              "description": "Starts with a cephalosporin derivative like GCLE. The C-7 amino group is protected by a phenylacetyl group. The C-3 acetoxymethyl group is converted to a chloromethyl group using trifluoroacetic acid."
            },
            {
              "step": "Step 2",
              "description": "The C-3 chloromethyl group undergoes nucleophilic substitution with N-methylpyrrolidine to form 7-phenylacetamido-3-[(1-methylpyrrolidinio)methyl]-3-cephem-4-carboxylic acid (3-NMP-DGCLE)."
            },
            {
              "step": "Step 3",
              "description": "The C-7 amino group is deprotected (cleaved) using an enzyme like immobilized penicillin acylase, yielding the key intermediate 7-amino-3-[(1-methylpyrrolidinio)methyl]-3-cephem-4-carboxylic acid (7-ACP)."
            },
            {
              "step": "Step 4",
              "description": "The C-7 amino group of 7-ACP is acylated with the AE-active ester to produce cefepime. The final product is then converted into dihydrochloride salt."
            }
          ],
          "note": "Specific process variations, including solvents, catalysts, and conditions, are often proprietary to manufacturers like Orchid Pharma, optimized for cost, yield, and purity.",
          "reference": [
            "https://patents.google.com/patent/CN101735251A/en",
            "https://patents.google.com/patent/CN102408440A/en"
          ]
        },
        "route2": {
          "name": "Route using GCLE (7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acid)",
          "description": "An alternative pathway described in patent literature uses GCLE as an early-stage intermediate.",
          "steps": [
            {
              "step": "1",
              "description": "Starting material: GCLE."
            },
            {
              "step": "2",
              "description": "Intermediates: 3-NMP-DGCLE: GCLE reacts with N-methylpyrrolidine to form 7-phenylacetamido-3-[(1-methyltetrahydropyrrole)methyl]-3-cephem-4-carboxylic acid. 7-ACP: Enzymatic deacylation of 3-NMP-DGCLE is performed to remove the phenylacetamido group and form 7-amino-3-[(1-methyltetrahydropyrrole)methyl]-3-ceph-4-carboxylic acid hydrochloride (7-ACP)."
            },
            {
              "step": "3",
              "description": "Final step: The 7-ACP is reacted with an AE-active ester in an acylation step to produce cefepime."
            }
          ]
        }
      },
      "polymorphStudies": "",
      "regulatoryStartingMaterials": {
        "startingMaterials": [
          {
            "name": "7-aminocephalosporanic acid (7-ACA)",
            "description": "This is the core cephalosporin building block."
          },
          {
            "name": "𝑁-Methylpyrrolidine",
            "description": "Used to add the characteristic side chain at the C-3 position of the cephalosporin nucleus."
          },
          {
            "name": "(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetic acid active ester (AE-active ester)",
            "description": "This provides the C-7 side chain."
          }
        ],
        "keyIntermediates": [
          {
            "name": "3-Chloromethyl derivative",
            "description": "The acetoxymethyl group of 7-ACA is first converted to a 3-chloromethyl group. This is often achieved using reagents like iodotrimethylsilane (TMSI) or other halogenating agents."
          },
          {
            "name": "7-phenylacetamido-3-(chloromethyl)-3-cephem-4-carboxylic acid (GCLE or DGCLE)",
            "description": "A precursor where the C-7 amino group is protected with a phenylacetyl group and the C-3 position has a chloromethyl group."
          },
          {
            "name": "7-amino-3-[(1-methyl-1-pyrrolidine)methyl]-3-cephem-4-carboxylic acid (7-ACP)",
            "description": "This is a crucial late-stage intermediate. It is formed by reacting the 3-chloromethyl derivative with 𝑁-methylpyrrolidine, followed by deacylation of the C-7 amino group using an enzyme like penicillin acylase."
          }
        ]
      },
      "rsmAndIntermediateSpecifications": "",
      "drugSubstanceSpecifications": "Appendix 2: DS Specification",
      "forcedDegradationStudies": "",
      "impurityQualification": "",
      "genotoxicImpuritiesAssessment": "",
      "nitrosaminesAssessment": "",
      "fateOfImpurities": "",
      "cppsAndCqaStudies": "",
      "otherInformation": "",
      "References": ""
    },
    "analyticalDevelopment": {
      "rsmMethods": "",
      "ipcTestMethods": "",
      "finalApiMethods": "",
      "residualSolventRiskAssessment": "",
      "rsmSynthesis": "",
      "stabilityOfDrugSubstance": "",
      "drugSubstanceSites": "",
      "dsImpurities": "",
      "dsImpurityMethods": "",
      "References": ""
    }
  },
  "drugProduct": {
    "information": {
      "dosageForms": "Intravenous use — supplied as a sterile powder for reconstitution in single-dose vials containing 2 g cefepime + 0.5 g enmetazobactam (2.5 g/vial). EMEA wording: powder for concentrate for solution for infusion; strength 2 g/0.5 g per vial",
      "strengths": [
        {
          "strength": "2.5 grams per vial",
          "composition": "2 grams cefepime and 0.5 grams enmetazobactam",
          "description": "powder for reconstitution in single-dose vials",
          "type": "powder for reconstitution"
        },
        {
          "strength": "1.25 grams",
          "composition": "1 gram cefepime and 0.25 grams enmetazobactam",
          "description": "Reduced dose for patients with renal impairment",
          "type": "powder for reconstitution"
        },
        {
          "strength": "0.625 grams",
          "composition": "0.5 grams cefepime and 0.125 grams enmetazobactam",
          "description": "Maintenance dose for severe renal impairment or hemodialysis",
          "type": "powder for reconstitution"
        }
      ],
      "dosingTable": {
        "description": "The recommended dosage of EXBLIFEP in patients 18 years of age and older with varying degrees of renal function is described in Table 1. For patients with changing renal function, monitor serum creatinine concentrations and eGFR at least daily and adjust the dosage of EXBLIFEP accordingly.",
        "notes": [
          "a As calculated using the Modification of Diet in Renal Disease (MDRD) formula",
          "b The total duration of treatment is for 7 to 14 days.",
          "c In patients requiring intermittent hemodialysis, complete the hemodialysis session before the start of EXBLIFEP dosing. Whenever possible, administer cefepime and enmetazobactam at the same time each day."
        ],
        "regimenByRenalFunction": [
          {
            "eGFR_mL_per_min": "Greater than or equal to 130",
            "dose": "EXBLIFEP 2.5 grams (2 grams cefepime and 0.5 grams enmetazobactam)",
            "dosingInterval": "Every 8 hours",
            "infusionTime": "4 hours"
          },
          {
            "eGFR_mL_per_min": "90 to 129",
            "dose": "EXBLIFEP 2.5 grams (2 grams cefepime and 0.5 grams enmetazobactam)",
            "dosingInterval": "Every 8 hours",
            "infusionTime": "2 hours"
          },
          {
            "eGFR_mL_per_min": "60 to 89",
            "dose": "EXBLIFEP 2.5 grams (2 grams cefepime and 0.5 grams enmetazobactam)",
            "dosingInterval": "Every 8 hours",
            "infusionTime": "2 hours"
          },
          {
            "eGFR_mL_per_min": "30 to 59",
            "dose": "EXBLIFEP 1.25 grams (1 gram cefepime and 0.25 grams enmetazobactam)",
            "dosingInterval": "Every 8 hours",
            "infusionTime": "2 hours"
          },
          {
            "eGFR_mL_per_min": "15 to 29",
            "dose": "EXBLIFEP 1.25 grams (1gram cefepime and 0.25 grams enmetazobactam)",
            "dosingInterval": "Every 12 hours",
            "infusionTime": "2 hours"
          },
          {
            "eGFR_mL_per_min": "less than 15 or receiving intermittent hemodialysis",
            "dose": "Loading dose of EXBLIFEP 1.25 grams (1 gram cefepime and 0.25 grams enmetazobactam) on the first day of treatment, followed by EXBLIFEP 0.625 grams (0.5 grams cefepime and 0.125 grams enmetazobactam)",
            "dosingInterval": "Every 24 hours",
            "infusionTime": "2 hours"
          }
        ]
      },
      "targetPopulation": "Adults (≥18 years). Pediatric use has not been established",
      "maximumDailyDose": "7.5 g/day total delivered as 2g of cefepime and 0.5g of enmetazobactam every 8 hours 7 days up to 14 days",
      "storageAndShippingConditions": "Store EXBLIFEP vials refrigerated at 2°C to 8°C (36°F to 46°F); excursions are permitted to 15°C to 25°C (59°F to 77°F) [see USP, Controlled Room Temperature (CRT)]. Keep the vials in the outer carton to protect from light.",
      "developmentProgramDesignation": "",
      "dpFormulation": "",
      "unmetClinicalNeed": "",
      "manufacturingProcess": "",
      "excipientsgGrade": "",
      "impurities": "",
      "specification": "",
      "testMethods": "",
      "residualSolventsRiskAssessment": "",
      "nitrosamineRiskAssessment": "",
      "stabilityStudies": "",
      "dissolutionStudies": "",
      "baBeStudies": "",
      "foodStudyReports": "",
      "currentLabel": "",
      "dpEmbossingDebossingInfo": "",
      "currentExpirationDating": "",
      "foodInteractions": "",
      "drugDrugInteractions": "",
      "packagingAndStorageConditions": {
        "description": "clear glass vials sealed with a rubber stopper (not made with natural rubber latex) and an aluminum overseal. Each vial is supplied in cartons of 10 vials (NDC 83289-101-02)",
        "packaging": "cartons of 10 vials",
        "ndc": "NDC 83289-101-02",
        "type": "vials",
        "storageTemperature": "Store EXBLIFEP vials refrigerated at 2°C to 8°C (36°F to 46°F); excursions are permitted to 15°C to 25°C (59°F to 77°F) [see USP, Controlled Room Temperature (CRT)]. Keep the vials in the outer carton to protect from light."
      },
      "labeling": "",
      "developmentProgramDesignationDetails": "Appendix 6: Development program designation",
      "References": ""
    }
  },
  "appendices": {
    "appendix1": {
      "name": "API Synthetic route",
      "reference": "",
      "description": "See manufacturing route in processDevelopment section",
      "modularSynthesis": {},
      "processDocumentation": "",
      "synthesisSteps": [],
      "currentManufacturers": ""
    },
    "appendix2": {
      "name": "DS Specification",
      "specifications": {
        "description": "https://www.ema.europa.eu/en/documents/assessment-report/xalkori-epar-public-assessment-report_en.pdf",
        "assay": "",
        "relatedSubstances": "",
        "chiral": "",
        "polymorph": "",
        "idByHplc": "",
        "idByFtir": "",
        "particleSizeDistribution": "",
        "residueOnIgnition": "",
        "heavyMetals": "",
        "palladium": ""
      }
    },
    "appendix3": {
      "name": "Formulation Composition",
      "note": "All excipients used in the formulation are compendial and are conventional for solid oral dosage forms.",
      "inactiveIngredients": [
        { "ingredientName": "SHELLAC (UNII: 46N107B71O)", "strength": "" },
        { "ingredientName": "PROPYLENE GLYCOL (UNII: 6DC9Q167V3)", "strength": "" },
        { "ingredientName": "AMMONIA (UNII: 5138Q19F1X)", "strength": "" },
        { "ingredientName": "POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)", "strength": "" },
        { "ingredientName": "FERROSOFERRIC OXIDE (UNII: XM0M87F357)", "strength": "" },
        { "ingredientName": "SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D)", "strength": "" }
      ]
    },
    "appendix4": {
      "name": "Preparation of Exblifep",
      "description": "EXBLIFEP is supplied as a dry powder in a single-dose vial that must be reconstituted and further diluted prior to intravenous infusion as outlined below. EXBLIFEP does not contain preservatives. Aseptic technique must be used for reconstitution and dilution.",
      "preparationSteps": [
        {
          "step": "1",
          "instruction": "Reconstitute the powder in the EXBLIFEP vial, with 10 mL of 0.9% Sodium Chloride Injection, or 5% Dextrose Injection, or 2.5% Dextrose and 0.45% Sodium Chloride Injection, from a 250 mL infusion bag."
        },
        {
          "step": "2",
          "instruction": "Mix gently to dissolve. The reconstituted EXBLIFEP solution will have a resultant concentration of 0.2 grams/mL (cefepime 0.16 grams/mL and enmetazobactam 0.04 grams/mL). The final volume is approximately 13 mL. The reconstituted solution is not for direct injection."
        },
        {
          "step": "3",
          "instruction": "The reconstituted solution must immediately be diluted further in the 250 mL infusion bag used in Step 1. The same injection solution should be used for both reconstitution and dilution (e.g., if reconstitution in Step 1 is performed with 5% dextrose, the dilution in Step 3 should be performed with a 250 mL infusion bag of 5% dextrose). To dilute the reconstituted solution, withdraw the full or partial reconstituted vial contents and add it back into the infusion bag in accordance with Table 2 below."
        },
        {
          "step": "4",
          "instruction": "Store the prepared diluted solution refrigerated at 2°C to 8°C (36°F to 46°F) for up to 4 hours prior to administration. The intravenous infusion administration of the diluted solution must be completed within 6 hours of dilution."
        },
        {
          "step": "5",
          "instruction": "Visually inspect the diluted EXBLIFEP solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The color of the EXBLIFEP infusion solution for administration is clear to yellowish. Discard unused portion after use."
        }
      ],
      "preparationTable": {
        "title": "Table 2: Preparation of EXBLIFEP Doses",
        "doses": [
          {
            "dose": "2.5 grams (2 grams cefepime and 0.5 grams enmetazobactam)",
            "numberOfVials": "1 vial",
            "volumeToWithdraw": "Entire contents (approximately 13 mL)",
            "infusionBagVolume": "250 mL"
          },
          {
            "dose": "1.25 grams (1 gram cefepime and 0.25 grams enmetazobactam)",
            "numberOfVials": "1 vial",
            "volumeToWithdraw": "Partial contents (6.5 mL)",
            "infusionBagVolume": "250 mL"
          },
          {
            "dose": "0.625 grams (0.5 grams cefepime and 0.125 grams enmetazobactam)",
            "numberOfVials": "1 vial",
            "volumeToWithdraw": "Partial contents (3.3 mL)",
            "infusionBagVolume": "250 mL"
          }
        ]
      },
      "labels": []
    },
    "appendix5": {
      "name": "Labeling Information",
      "description": "",
      "labels": []
    },
    "appendix6": {
      "name": "Development program designation",
      "description": "",
      "designations": {}
    }
  },
  "references": []
}
]


